Cargando…
IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis
The aim of our work was to investigate the role of interleukin-33 (IL-33) and its receptor ST2 in the progression of diet-induced nonalcoholic steatohepatitis (NASH) in mice, and the characteristic expression in livers of patients with NASH. Mice were fed with high-fat diet (HFD) or methionine-choli...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085109/ https://www.ncbi.nlm.nih.gov/pubmed/27172901 http://dx.doi.org/10.18632/oncotarget.9259 |
_version_ | 1782463504854286336 |
---|---|
author | Gao, Yinjie Liu, Yuan Yang, Mei Guo, Xiaodong Zhang, Min Li, Hanwei Li, Jin Zhao, Jingmin |
author_facet | Gao, Yinjie Liu, Yuan Yang, Mei Guo, Xiaodong Zhang, Min Li, Hanwei Li, Jin Zhao, Jingmin |
author_sort | Gao, Yinjie |
collection | PubMed |
description | The aim of our work was to investigate the role of interleukin-33 (IL-33) and its receptor ST2 in the progression of diet-induced nonalcoholic steatohepatitis (NASH) in mice, and the characteristic expression in livers of patients with NASH. Mice were fed with high-fat diet (HFD) or methionine-choline 4-deficient diet (MCD) and injected intraperitoneally with IL-33. Both mRNA and protein expression levels of IL-33 and ST2 were up-regulated in the livers of mice fed with HFD or MCD. Treatment with IL-33 attenuated diet-induced hepatic steatosis and reduced activities of ALT in serum, as well as ameliorated HFD-induced systemic insulin resistance and glucose intolerance, while aggravated hepatic fibrosis in diet-induced NASH. Furthermore, treatment with IL-33 can also promote Th2 response and M2 macrophage activation and beneficial modulation on expression profiles of fatty acid metabolism genes in livers. ST2 deficiency did not affect hepatic steatosis and fibrosis when fed with controlling diet. IL-33 did not affect diet-induced hepatic steatosis and fibrosis in ST2 knockout mice. Meanwhile, in the livers of patients with NASH, IL-33 was mainly located in hepatic sinusoid, endothelial cells, and hepatic stellate cells. The mRNA expression level of IL-33 and ST2 was elevated with the progression of NASH. In conclusion, treatment with IL-33 attenuated diet-induced hepatic steatosis, but aggravated hepatic fibrosis, in a ST2-dependent manner. |
format | Online Article Text |
id | pubmed-5085109 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-50851092016-10-31 IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis Gao, Yinjie Liu, Yuan Yang, Mei Guo, Xiaodong Zhang, Min Li, Hanwei Li, Jin Zhao, Jingmin Oncotarget Research Paper: Pathology The aim of our work was to investigate the role of interleukin-33 (IL-33) and its receptor ST2 in the progression of diet-induced nonalcoholic steatohepatitis (NASH) in mice, and the characteristic expression in livers of patients with NASH. Mice were fed with high-fat diet (HFD) or methionine-choline 4-deficient diet (MCD) and injected intraperitoneally with IL-33. Both mRNA and protein expression levels of IL-33 and ST2 were up-regulated in the livers of mice fed with HFD or MCD. Treatment with IL-33 attenuated diet-induced hepatic steatosis and reduced activities of ALT in serum, as well as ameliorated HFD-induced systemic insulin resistance and glucose intolerance, while aggravated hepatic fibrosis in diet-induced NASH. Furthermore, treatment with IL-33 can also promote Th2 response and M2 macrophage activation and beneficial modulation on expression profiles of fatty acid metabolism genes in livers. ST2 deficiency did not affect hepatic steatosis and fibrosis when fed with controlling diet. IL-33 did not affect diet-induced hepatic steatosis and fibrosis in ST2 knockout mice. Meanwhile, in the livers of patients with NASH, IL-33 was mainly located in hepatic sinusoid, endothelial cells, and hepatic stellate cells. The mRNA expression level of IL-33 and ST2 was elevated with the progression of NASH. In conclusion, treatment with IL-33 attenuated diet-induced hepatic steatosis, but aggravated hepatic fibrosis, in a ST2-dependent manner. Impact Journals LLC 2016-05-09 /pmc/articles/PMC5085109/ /pubmed/27172901 http://dx.doi.org/10.18632/oncotarget.9259 Text en Copyright: © 2016 Gao et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper: Pathology Gao, Yinjie Liu, Yuan Yang, Mei Guo, Xiaodong Zhang, Min Li, Hanwei Li, Jin Zhao, Jingmin IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis |
title | IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis
|
title_full | IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis
|
title_fullStr | IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis
|
title_full_unstemmed | IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis
|
title_short | IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis
|
title_sort | il-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis |
topic | Research Paper: Pathology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085109/ https://www.ncbi.nlm.nih.gov/pubmed/27172901 http://dx.doi.org/10.18632/oncotarget.9259 |
work_keys_str_mv | AT gaoyinjie il33treatmentattenuateddietinducedhepaticsteatosisbutaggravatedhepaticfibrosis AT liuyuan il33treatmentattenuateddietinducedhepaticsteatosisbutaggravatedhepaticfibrosis AT yangmei il33treatmentattenuateddietinducedhepaticsteatosisbutaggravatedhepaticfibrosis AT guoxiaodong il33treatmentattenuateddietinducedhepaticsteatosisbutaggravatedhepaticfibrosis AT zhangmin il33treatmentattenuateddietinducedhepaticsteatosisbutaggravatedhepaticfibrosis AT lihanwei il33treatmentattenuateddietinducedhepaticsteatosisbutaggravatedhepaticfibrosis AT lijin il33treatmentattenuateddietinducedhepaticsteatosisbutaggravatedhepaticfibrosis AT zhaojingmin il33treatmentattenuateddietinducedhepaticsteatosisbutaggravatedhepaticfibrosis |